Organovo Holdings, Inc. (ONVO)
- Previous Close
0.4523 - Open
0.4462 - Bid 0.3784 x 100
- Ask 0.5157 x 100
- Day's Range
0.4400 - 0.4523 - 52 Week Range
0.4000 - 2.0500 - Volume
32,185 - Avg. Volume
62,853 - Market Cap (intraday)
6.95M - Beta (5Y Monthly) 0.61
- PE Ratio (TTM)
-- - EPS (TTM)
-1.3700 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.10
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised of mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company's lead candidate is FXR314, which is phase 2/3clinical trial for indication of inflammatory bowel disease with a clinical focus on ulcerative colitis; and completed phase 1 clinical trial for the indication of liver fibrosis with a clinical focus steatohepatitis. Organovo Holdings, Inc. has research collaborations with Yale School of Medicine, Knight Cancer Institute at Oregon Health & Science University, and the University of Virginia for research of NovoGen Bioprinters. The company was incorporated in 2007 and is headquartered in San Diego, California.
www.organovo.comRecent News: ONVO
View MorePerformance Overview: ONVO
Trailing total returns as of 10/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ONVO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ONVO
View MoreValuation Measures
Market Cap
6.95M
Enterprise Value
2.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
65.87
Price/Book (mrq)
1.04
Enterprise Value/Revenue
28.05
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-73.67%
Return on Equity (ttm)
-151.72%
Revenue (ttm)
73k
Net Income Avi to Common (ttm)
-13.99M
Diluted EPS (ttm)
-1.3700
Balance Sheet and Cash Flow
Total Cash (mrq)
6.19M
Total Debt/Equity (mrq)
19.29%
Levered Free Cash Flow (ttm)
-7.39M